Pharmacological lipid-modification therapies for prevention of ischaemic heart disease

current and future options

Kausik K. Ray, Pablo Corral, Enrique Morales, Stephen J. Nicholls

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Atherosclerosis and its clinical manifestation as ischaemic heart disease remains a considerable health burden. Given that many factors contribute to ischaemic heart disease, a multifactorial approach to prevention is recommended, starting with lifestyle advice, smoking cessation, and control of known cardiovascular risk factors, such as blood pressure and lipids. Within the lipid profile, the principal target is lowering LDL cholesterol, firstly with lifestyle interventions and subsequently with pharmacological therapy. Statins are the recommended first-line pharmacological treatment. Some individuals might require further lowering of LDL cholesterol or be unable to tolerate statins. Additional therapies targeting different pathways in cholesterol metabolism are now available, ranging from small molecules taken orally, to injectable therapies. Examples include ezetimibe, which targets Niemann-Pick C1-like protein, and monoclonal antibodies that target PCSK9. Phase 3 trials have also been completed for bempedoic acid (targeting ATP-citrate lyase) and inclisiran (an interference RNA-based therapeutic targeting hepatic PCSK9 synthesis). In addition to LDL cholesterol, mendelian randomisation studies support a causal role for lipoprotein(a) and triglycerides in ischaemic heart disease. In this Series paper, we appraise currently available and emerging therapies for lowering LDL cholesterol, lipoprotein(a), and triglycerides for prevention of ischaemic heart disease.

Original languageEnglish
Pages (from-to)697-708
Number of pages12
JournalThe Lancet
Volume394
Issue number10199
DOIs
Publication statusPublished - 24 Aug 2019

Cite this

Ray, Kausik K. ; Corral, Pablo ; Morales, Enrique ; Nicholls, Stephen J. / Pharmacological lipid-modification therapies for prevention of ischaemic heart disease : current and future options. In: The Lancet. 2019 ; Vol. 394, No. 10199. pp. 697-708.
@article{c5996b7fe6d446fb9cd117d14f7fb38a,
title = "Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options",
abstract = "Atherosclerosis and its clinical manifestation as ischaemic heart disease remains a considerable health burden. Given that many factors contribute to ischaemic heart disease, a multifactorial approach to prevention is recommended, starting with lifestyle advice, smoking cessation, and control of known cardiovascular risk factors, such as blood pressure and lipids. Within the lipid profile, the principal target is lowering LDL cholesterol, firstly with lifestyle interventions and subsequently with pharmacological therapy. Statins are the recommended first-line pharmacological treatment. Some individuals might require further lowering of LDL cholesterol or be unable to tolerate statins. Additional therapies targeting different pathways in cholesterol metabolism are now available, ranging from small molecules taken orally, to injectable therapies. Examples include ezetimibe, which targets Niemann-Pick C1-like protein, and monoclonal antibodies that target PCSK9. Phase 3 trials have also been completed for bempedoic acid (targeting ATP-citrate lyase) and inclisiran (an interference RNA-based therapeutic targeting hepatic PCSK9 synthesis). In addition to LDL cholesterol, mendelian randomisation studies support a causal role for lipoprotein(a) and triglycerides in ischaemic heart disease. In this Series paper, we appraise currently available and emerging therapies for lowering LDL cholesterol, lipoprotein(a), and triglycerides for prevention of ischaemic heart disease.",
author = "Ray, {Kausik K.} and Pablo Corral and Enrique Morales and Nicholls, {Stephen J.}",
year = "2019",
month = "8",
day = "24",
doi = "10.1016/S0140-6736(19)31950-6",
language = "English",
volume = "394",
pages = "697--708",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "10199",

}

Pharmacological lipid-modification therapies for prevention of ischaemic heart disease : current and future options. / Ray, Kausik K.; Corral, Pablo; Morales, Enrique; Nicholls, Stephen J.

In: The Lancet, Vol. 394, No. 10199, 24.08.2019, p. 697-708.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Pharmacological lipid-modification therapies for prevention of ischaemic heart disease

T2 - current and future options

AU - Ray, Kausik K.

AU - Corral, Pablo

AU - Morales, Enrique

AU - Nicholls, Stephen J.

PY - 2019/8/24

Y1 - 2019/8/24

N2 - Atherosclerosis and its clinical manifestation as ischaemic heart disease remains a considerable health burden. Given that many factors contribute to ischaemic heart disease, a multifactorial approach to prevention is recommended, starting with lifestyle advice, smoking cessation, and control of known cardiovascular risk factors, such as blood pressure and lipids. Within the lipid profile, the principal target is lowering LDL cholesterol, firstly with lifestyle interventions and subsequently with pharmacological therapy. Statins are the recommended first-line pharmacological treatment. Some individuals might require further lowering of LDL cholesterol or be unable to tolerate statins. Additional therapies targeting different pathways in cholesterol metabolism are now available, ranging from small molecules taken orally, to injectable therapies. Examples include ezetimibe, which targets Niemann-Pick C1-like protein, and monoclonal antibodies that target PCSK9. Phase 3 trials have also been completed for bempedoic acid (targeting ATP-citrate lyase) and inclisiran (an interference RNA-based therapeutic targeting hepatic PCSK9 synthesis). In addition to LDL cholesterol, mendelian randomisation studies support a causal role for lipoprotein(a) and triglycerides in ischaemic heart disease. In this Series paper, we appraise currently available and emerging therapies for lowering LDL cholesterol, lipoprotein(a), and triglycerides for prevention of ischaemic heart disease.

AB - Atherosclerosis and its clinical manifestation as ischaemic heart disease remains a considerable health burden. Given that many factors contribute to ischaemic heart disease, a multifactorial approach to prevention is recommended, starting with lifestyle advice, smoking cessation, and control of known cardiovascular risk factors, such as blood pressure and lipids. Within the lipid profile, the principal target is lowering LDL cholesterol, firstly with lifestyle interventions and subsequently with pharmacological therapy. Statins are the recommended first-line pharmacological treatment. Some individuals might require further lowering of LDL cholesterol or be unable to tolerate statins. Additional therapies targeting different pathways in cholesterol metabolism are now available, ranging from small molecules taken orally, to injectable therapies. Examples include ezetimibe, which targets Niemann-Pick C1-like protein, and monoclonal antibodies that target PCSK9. Phase 3 trials have also been completed for bempedoic acid (targeting ATP-citrate lyase) and inclisiran (an interference RNA-based therapeutic targeting hepatic PCSK9 synthesis). In addition to LDL cholesterol, mendelian randomisation studies support a causal role for lipoprotein(a) and triglycerides in ischaemic heart disease. In this Series paper, we appraise currently available and emerging therapies for lowering LDL cholesterol, lipoprotein(a), and triglycerides for prevention of ischaemic heart disease.

UR - http://www.scopus.com/inward/record.url?scp=85070926651&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(19)31950-6

DO - 10.1016/S0140-6736(19)31950-6

M3 - Review Article

VL - 394

SP - 697

EP - 708

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10199

ER -